Stoke Therapeutics, Inc. Selling, General and Administrative Expense
Stoke Therapeutics, Inc. (STOK) reported Selling, General and Administrative Expense of $25.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- Stoke Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $25.25M, a 65.46% increase year-over-year.
- Stoke Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $19.97M, a 36.31% increase year-over-year.
- Stoke Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $21.15M, a 64.64% increase year-over-year.
- Stoke Therapeutics, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $16.03M, a 26.28% increase year-over-year.
- Stoke Therapeutics, Inc. selling, general and administrative expense for fiscal 2025 was $67.09M, a 37.49% increase from fiscal 2024.
- Stoke Therapeutics, Inc. selling, general and administrative expense for fiscal 2024 was $48.79M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.25M 10-Q · filed 2026-08-03 | $45.23M 10-Q · filed 2026-08-03 | $66.37M derived: sum of 3 quarters · filed 2026-08-03 | $82.40M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $19.97M 10-Q · filed 2026-05-07 | $41.12M derived: sum of 2 quarters · filed 2026-05-07 | $57.15M derived: sum of 3 quarters · filed 2026-05-07 | $72.41M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $21.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $37.17M derived: sum of 2 quarters · filed 2026-03-16 | $52.44M derived: sum of 3 quarters · filed 2026-08-03 | $67.09M 10-K · filed 2026-03-16 |
| 2025-09-30 | $16.03M 10-Q · filed 2025-11-04 | $31.29M derived: sum of 2 quarters · filed 2026-08-03 | $45.94M 10-Q · filed 2025-11-04 | $58.79M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $15.26M 10-Q · filed 2026-08-03 | $29.91M 10-Q · filed 2026-08-03 | $42.76M derived: sum of 3 quarters · filed 2026-08-03 | $55.45M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $14.65M 10-Q · filed 2026-05-07 | $27.50M derived: sum of 2 quarters · filed 2026-05-07 | $40.19M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $12.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $25.54M derived: sum of 2 quarters · filed 2026-03-16 | $48.79M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $12.69M 10-Q · filed 2025-11-04 | $35.95M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |